HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1532-1547

  Gupta, Parul ^a   Srivastava, Sanjay K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Breast cancer; Invivo

Indexed keywords

ANTIMETASTATIC AGENT; BETA CATENIN; CUCURBITACIN; CUCURBITACIN B; CYTOKERATIN 18; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERVE CELL ADHESION MOLECULE; SMAD PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL INVASION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; BREAST TUMOR; CHROMATIN IMMUNOPRECIPITATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84911972745     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.06.006     Document Type: Article

References (40)

1. Arend R.C., Londono-Joshi A.I., Straughn J.M., Buchsbaum D.J. The Wnt/Beta-catenin pathway in ovarian cancer: a review. Gynecol. Oncol. 2013, 131:772-779.
2. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W. Functional interaction of Beta-catenin with the transcription factor Lef-1. Nature 1996, 382:638-642.
3. Boreddy S.R., Sahu R.P., Srivastava S.K. Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting Hif-Alpha/Vegf/Rho-Gtpases: pivotal role of Stat-3. PLoS One 2011, 6:e25799.
4. Brandl M., Seidler B., Haller F., Adamski J., Schmid R.M., Saur D., Schneider G. Ikk(Alpha) controls canonical TGF(Ss)-Smad signaling to regulate genes expressing snail and slug during Emt in Panc1 cells. J.Cell Sci. 2010, 123:4231-4239.
5. Brufsky A.M., Mayer M., Rugo H.S., Kaufman P.A., Tan-Chiu E., Tripathy D., Tudor I.C., Wang L.I., Brammer M.G., Shing M., Yood M.U., Yardley D.A. Central nervous system metastases in patients with Her2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin. Cancer Res. 2011, 17:4834-4843.
6. de Herreros A.G., Peiro S., Nassour M., Savagner P. Snail family regulation and epithelial mesenchymal transitions in breast Cancer progression. J.Mammary Gland Biol. Neoplasia 2010, 15:135-147.
7. Fagotto F. Looking beyond the Wnt pathway for the deep nature of Beta-catenin. EMBO Rep. 2013, 14:422-433.
8. Gheldof A., Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog. Mol. Biol. Transl. Sci. 2013, 116:317-336.
9. Gupta P., Adkins C., Lockman P., Srivastava S. Metastasis of breast tumor cells to brain is suppressed by phenethyl isothiocyanate in a novel invivo metastasis model. PLoS One 2013, 8.
10. Gupta P., Srivastava S.K. Antitumor activity of phenethyl isothiocyanate in Her2-positive breast Cancer models. BMC Med. 2012, 10:80.
11. Gupta P., Srivastava S.K. Inhibition of Her2-integrin signaling by cucurbitacin B leads to invitro and invivo breast tumor growth suppression. Oncotarget 2014, 5:1812-1828.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Harari D., Yarden Y. Molecular mechanisms underlying Erbb2/Her2 action in breast cancer. Oncogene 2000, 19:6102-6114.
14. Huang F., Reeves K., Han X., Fairchild C., Platero S., Wong T.W., Lee F., Shaw P., Clark E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007, 67:2226-2238.
15. Irvin W., Muss H.B., Mayer D.K. Symptom management in metastatic breast cancer. Oncologist 2011, 16:1203-1214.
16. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA - A Cancer J. Clin. 2011, 61:69-90.
17. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J.Clin. Invest. 2009, 119:1420-1428.
18. Kapoor S. Cucurbitacin B and its rapidly emerging role in the management of systemic malignancies besides lung carcinomas. Cancer Biother. Radiopharm 2013, 28:359.
19. Katsuno Y., Lamouille S., Derynck R. TGF-Beta signaling and epithelial-mesenchymal transition in Cancer progression. Curr. Opin. Oncol. 2013, 25:76-84.
20. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast Cancer subtypes. J.Clin. Oncol. 2010, 28:3271-3277.
21. Li P., Jing J., Hu J., Li T., Sun Y., Guan H. Rna Interference targeting snail inhibits the transforming growth factor Beta 2-induced epithelial-mesenchymal transition in human lens epithelial cells. J.Ophthalmol. 2013, 2013:869101.
22. Mallini P., Lennard T., Kirby J., Meeson A. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat. Rev. 2014, 40:341-348.
23. Nahta R. Pharmacological strategies to overcome Her2 cross-talk and trastuzumab resistance. Curr. Med. Chem. 2012, 19:1065-1075.
24. Nam J.S., Terabe M., Mamura M., Kang M.J., Chae H., Stuelten C., Kohn E., Tang B., Sabzevari H., Anver M.R., Lawrence S., Danielpour D., Lonning S., Berzofsky J.A., Wakefield L.M. An anti-transforming growth factor Beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 2008, 68:3835-3843.
25. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast Cancer. Oncologist 2005, 10(Suppl. 3):20-29.
26. Oliveras-Ferraros C., Corominas-Faja B., Cufi S., Vazquez-Martin A., Martin-Castillo B., Iglesias J.M., Lopez-Bonet E., Martin A.G., Menendez J.A. Epithelial-to-mesenchymal transition (Emt) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 2012, 11:4020-4032.
27. Padua D., Massague J. Roles of TGF-Beta in metastasis. Cell Res. 2009, 19:89-102.
28. Palmieri D., Bronder J.L., Herring J.M., Yoneda T., Weil R.J., Stark A.M., Kurek R., Vega-Valle E., Feigenbaum L., Halverson D., Vortmeyer A.O., Steinberg S.M., Aldape K., Steeg P.S. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007, 67:4190-4198.
29. Sahu R.P., Batra S., Srivastava S.K. Activation of Atm/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br. J. Cancer 2009, 100:1425-1433.
30. Sahu R.P., Srivastava S.K. The role of Stat-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. J.Natl. Cancer Inst. 2009, 101:176-193.
31. Sanchez-Tillo E., de Barrios O., Siles L., Cuatrecasas M., Castells A., Postigo A. Beta-Catenin/Tcf4 complex induces the epithelial-to-mesenchymal transition (Emt)-Activator Zeb1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19204-19209.
32. Saunier E.F., Akhurst R.J. TGF Beta inhibition for Cancer therapy. Curr. Cancer Drug Targets 2006, 6:565-578.
33. Schade B., Lesurf R., Sanguin-Gendreau V., Bui T., Deblois G., O'Toole S.A., Millar E.K., Zardawi S.J., Lopez-Knowles E., Sutherland R.L., Giguere V., Kahn M., Hallett M., Muller W.J. Beta-catenin signaling is a critical event in Erbb2-mediated mammary tumor progression. Cancer Res. 2013, 73:4474-4487.
34. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/Neu oncogene. Science 1987, 235:177-182.
35. Taylor M.A., Parvani J.G., Schiemann W.P. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J.Mammary Gland Biol. Neoplasia 2010, 15:169-190.
36. Thoennissen N.H., Iwanski G.B., Doan N.B., Okamoto R., Lin P., Abbassi S., Song J.H., Yin D., Toh M., Xie W.D., Said J.W., Koeffler H.P. Cucurbitacin B induces apoptosis by inhibition of the Jak/Stat pathway and potentiates antiproliferative effects of gemcitabine on pancreatic Cancer cells. Cancer Res. 2009, 69:5876-5884.
37. Tsai J.H., Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013, 27:2192-2206.
38. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of Her2-overexpressing metastatic breast cancer. J.Clin. Oncol. 2002, 20:719-726.
39. Wang S.E. The functional crosstalk between Her2 tyrosine kinase and TGF-Beta signaling in breast cancer malignancy. J.Signal Transduction 2011, 2011:804236.
40. Yang Z.C., Yi M.J., Ran N., Wang C., Fu P., Feng X.Y., Xu L., Qu Z.H. Transforming growth factor-beta1 induces bronchial epithelial cells to mesenchymal transition by activating the snail pathway and promotes airway remodeling in asthma. Mol. Med. Rep. 2013, 8:1663-1668.